Paying users zone. Data is covered by 
.
Get 1 month access to Pfizer Inc. for $19.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Pfizer Inc. (PFE)
Liquidity Analysis
Difficulty: Beginner
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Ratios (Summary)
Pfizer Inc., liquidity ratios
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Current ratio | |
|
|
|
|
|
| Quick ratio | |
|
|
|
|
|
| Cash ratio | |
|
|
|
|
Based on: 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29), 10-K (filing date: 2015-02-27).
| Ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Pfizer Inc.’s current ratio improved from 2016 to 2017 and from 2017 to 2018. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Pfizer Inc.’s quick ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Pfizer Inc.’s cash ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level. |
Current Ratio
Pfizer Inc., current ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Current assets | |
|
|
|
|
|
| Current liabilities | |
|
|
|
|
|
| Ratio | ||||||
| Current ratio1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Current Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Current Ratio, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Pfizer Inc.’s current ratio improved from 2016 to 2017 and from 2017 to 2018. |
Quick Ratio
Pfizer Inc., quick ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Cash and cash equivalents | |
|
|
|
|
|
| Short-term investments | |
|
|
|
|
|
| Trade accounts receivable, less allowance for doubtful accounts | |
|
|
|
|
|
| Total quick assets | |
|
|
|
|
|
| Current liabilities | |
|
|
|
|
|
| Ratio | ||||||
| Quick ratio1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Quick Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Quick Ratio, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Pfizer Inc.’s quick ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level. |
Cash Ratio
Pfizer Inc., cash ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Cash and cash equivalents | |
|
|
|
|
|
| Short-term investments | |
|
|
|
|
|
| Total cash assets | |
|
|
|
|
|
| Current liabilities | |
|
|
|
|
|
| Ratio | ||||||
| Cash ratio1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Cash Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Cash Ratio, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Pfizer Inc.’s cash ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level. |